Cristiana Bergamini

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 5

Top Topics

Ejection Fraction

Vascular Endothelial Growth Factor

Liver Metastases

Top Venues

Exploration of targeted anti-tumor therapy

Expert opinion on investigational drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Stefano Cavalieri, Elena Colombo, Achille Bottiglieri, Giacomo Massa, Francesca Platini, Arianna Ottini, Daria Maria Filippini, Emma Zattarin, Cristiana Bergamini, Carlo Resteghini, Salvatore Alfieri, Vito Di Martino, Valentina Tiraferri, Laura Deborah Locati, Lisa Licitra
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic. Tumori (2021)
Cristiana Bergamini, Robert L Ferris, Jing Xie, Gabriella Mariani, Muzammil Ali, William C Holmes, Kevin Harrington, Amanda Psyrri, Stefano Cavalieri, Lisa Licitra
Bleeding complications in patients with squamous cell carcinoma of the head and neck. Head & neck 43 (9) (2021)
Stefano Cavalieri, Daria Maria Filippini, Arianna Ottini, Cristiana Bergamini, Carlo Resteghini, Elena Colombo, Roberta Lombardo, Imperia Nuzzolese, Salvatore Alfieri, Lisa F Licitra, Laura Deborah Locati
Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. Exploration of targeted anti-tumor therapy 2 (6) (2021)
Cristiana Bergamini, Stefano Cavalieri, Tommaso Cascella, Rodolfo Lanocita, Salvatore Alfieri, Carlo Resteghini, Francesca Platini, Ester Orlandi, Laura Deborah Locati, Alfonso Marchianò, Lisa Licitra
Local therapies for liver metastases of rare head and neck cancers: a monoinstitutional case series. Tumori 107 (3) (2020)
Stefano Cavalieri, Francesca Platini, Cristiana Bergamini, Carlo Resteghini, Donata Galbiati, Paolo Bossi, Federica Perrone, Elena Tamborini, Pasquale Quattrone, Lisa F Licitra, Laura Deborah Locati, Salvatore Alfieri
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? Expert opinion on investigational drugs 28 (5) (2019)